Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.66 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865068 | 0.83 | ALDH1A1 (0.59) | HCRTR1HCRTR2ALDH1A1KDM4EHTT | |
| SCHEMBL13865070 | 0.81 | HCRTR1 (0.67) | HCRTR1HCRTR2MEN1KMT2ATSHR | |
| SCHEMBL4483151 | 0.80 | HCRTR1 (1.00) | HCRTR1HCRTR2ALDH1A1CHRM3 | |
| SCHEMBL8251291 | 0.79 | MEN1 (0.66) | HCRTR1HCRTR2ALDH1A1MEN1KMT2A | |
| SCHEMBL13868025 | 0.79 | MEN1 (0.66) | HCRTR1HCRTR2ALDH1A1MEN1KMT2A | |
| SCHEMBL4486880 | 0.79 | HCRTR1 (1.00) | HCRTR1HCRTR2KDM4E | |
| SCHEMBL8254625 | 0.78 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL4486323 | 0.78 | HCRTR1 (0.82) | HCRTR1HCRTR2CHRM3TSHRL3MBTL1 | |
| SCHEMBL27776460 | 0.77 | HCRTR1 (0.54) | HCRTR1HCRTR2ALDH1A1MEN1KMT2A | |
| SCHEMBL4489998 | 0.77 | HCRTR1 (0.83) | HCRTR1HCRTR2MEN1KMT2ACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | HCRTR1, HCRTR2, NPSR1 | HCRTR1 1/4885HCRTR2 2/4885ALDH1A1 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.